In recent years, immunotherapy have gained attention due to favourable results obtained with immunological checkpoint inhibitors targeting cytotoxic T lymphocyte- associated antigen 4 (CTLA-4), ipilimumab and programmed cell death-1 (PD-1) pembrolizumab, in the management of cutaneous melanoma [143,144]. Here, CTLA4 is linked to cutaneous melanoma.